ATE307572T1 - Verbesserte hmg coa reduktase-inhibitor formulierung mit verlängerter freisetzung - Google Patents

Verbesserte hmg coa reduktase-inhibitor formulierung mit verlängerter freisetzung

Info

Publication number
ATE307572T1
ATE307572T1 AT98960752T AT98960752T ATE307572T1 AT E307572 T1 ATE307572 T1 AT E307572T1 AT 98960752 T AT98960752 T AT 98960752T AT 98960752 T AT98960752 T AT 98960752T AT E307572 T1 ATE307572 T1 AT E307572T1
Authority
AT
Austria
Prior art keywords
improved
coa reductase
release formulation
extended release
reductase inhibitor
Prior art date
Application number
AT98960752T
Other languages
English (en)
Inventor
Chih-Ming Chen
Joseph Chou
David Wong
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE307572T1 publication Critical patent/ATE307572T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98960752T 1997-12-12 1998-12-04 Verbesserte hmg coa reduktase-inhibitor formulierung mit verlängerter freisetzung ATE307572T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/989,253 US5916595A (en) 1997-12-12 1997-12-12 HMG co-reductase inhibitor
PCT/US1998/025766 WO1999030692A1 (en) 1997-12-12 1998-12-04 IMPROVED HMG CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION

Publications (1)

Publication Number Publication Date
ATE307572T1 true ATE307572T1 (de) 2005-11-15

Family

ID=25534912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960752T ATE307572T1 (de) 1997-12-12 1998-12-04 Verbesserte hmg coa reduktase-inhibitor formulierung mit verlängerter freisetzung

Country Status (9)

Country Link
US (1) US5916595A (de)
EP (1) EP1035842B1 (de)
JP (2) JP4646400B2 (de)
AT (1) ATE307572T1 (de)
AU (1) AU737962B2 (de)
CA (1) CA2315329C (de)
DE (1) DE69832092T2 (de)
ES (1) ES2252872T3 (de)
WO (1) WO1999030692A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
SE9801429D0 (sv) * 1998-04-23 1998-04-23 Siemens Elema Ab Förgasare
JP2002538202A (ja) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド HMG−CoAレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1036563A1 (de) * 1999-03-08 2000-09-20 MERCK & CO. INC. Dihydroxy offen Saüre und Salzen von hmg-coa reductase Inhibitoren
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
WO2001032162A1 (en) * 1999-11-03 2001-05-10 Howard J. Smith & Associates Pty Ltd Liver selective therapy
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
CA2389973A1 (en) * 1999-11-04 2001-05-10 Andrx Corporation Method of treating amyloid beta precursor disorders
EP1233761B1 (de) * 1999-11-22 2007-03-28 ALZA Corporation Osmotische darreichungsform mit zwei mantelschichten
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
DE60211808T2 (de) * 2001-07-31 2006-10-19 Kabushiki Kaisha Kobe Seiko Sho (Kobe Steel, Ltd.), Kobe Plattierte Kupferlegierung und Verfahren zu ihre Herstellung
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
MXPA04006780A (es) * 2002-01-11 2005-06-08 Athpharma Ltd Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
EP1905431A1 (de) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20040132806A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
US20040132802A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pharmaceutical formulations and methods for modified release of statin drugs
SI21400A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Cetp 억제제의 약제학적 조성물
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
AU2005247195A1 (en) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
WO2006054307A2 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
US20080260818A1 (en) * 2005-03-28 2008-10-23 Dexcel Pharma Technologies Ltd. Controlled Absorption of Statins in the Intestine
AU2006263337A1 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070098746A1 (en) * 2005-11-02 2007-05-03 Nichols William M Multi-layered coating technology for taste masking
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
MX2012007370A (es) * 2009-12-22 2012-10-05 Re Community Energy Llc Cargas de alimentación de combustible diseñadas que contienen adsorbente.
CN102670557A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 洛伐他汀渗透泵型控释片
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AR089765A1 (es) * 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
CN104069502B (zh) 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
CN107920995A (zh) 2015-07-02 2018-04-17 路易斯威尔大学研究基金会 用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4976967A (en) * 1987-08-03 1990-12-11 Merck & Co., Inc. Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5300288A (en) * 1991-04-05 1994-04-05 Rohm And Haas Company Composition and method for controlling cholesterol
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
IN176897B (de) * 1993-10-29 1996-09-28 Cadila Lab Ltd
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core

Also Published As

Publication number Publication date
EP1035842B1 (de) 2005-10-26
CA2315329C (en) 2008-04-29
US5916595A (en) 1999-06-29
CA2315329A1 (en) 1999-06-24
WO1999030692A1 (en) 1999-06-24
AU1627599A (en) 1999-07-05
DE69832092D1 (de) 2005-12-01
DE69832092T2 (de) 2006-07-13
AU737962B2 (en) 2001-09-06
JP2002508311A (ja) 2002-03-19
JP2010229150A (ja) 2010-10-14
JP4646400B2 (ja) 2011-03-09
ES2252872T3 (es) 2006-05-16
JP5132721B2 (ja) 2013-01-30
EP1035842A4 (de) 2003-07-23
EP1035842A1 (de) 2000-09-20

Similar Documents

Publication Publication Date Title
DE69832092D1 (de) VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG
FI973452A7 (fi) Nauhoitettu annosmuoto aktiivisen aineen pidennettyyn jakamiseen
ATE287260T1 (de) Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung
EP0815853A3 (de) Langsam freisetzende Zubereitung für bioaktive Substanz mit einer sauren Gruppe
WO2004108067A3 (en) Programmed drug delivery system
AU7562896A (en) Water soluble films
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
PT801560E (pt) Um dispositivo de libertacao controlada de um farmaco em suspensao
SV1998000104A (es) Formas de dosificacion farmaceuticas solidas
DE69925133D1 (de) Pyrrolobenzodiazepine
AU2016992A (en) Multi-layered controlled release formulation
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
AU4230900A (en) Purposeful movement of human migratory cells away from an agent source
WO2002024174A3 (en) Sustained release composition containing clarithromycin
ES2175362T3 (es) Agente fitosanitario solido.
BR0108753A (pt) Corpos sólidos
PT1263745E (pt) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao para a inibicao da lipase sensivel a hormonas
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
NO995267D0 (no) Leptin som en inhibitor av tumorcelleprofilering
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
AU3483497A (en) Solid solution of an antifungal agent with enhanced bioavailability
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
EP0761095A3 (de) Vorbehandlungszusammensetzung für die Haut
EP1291713A3 (de) Thermisch entwickelbare Bildaufzeichnungsmaterialien, die eine Hydroxylgruppen enthaltende polymere Trennschicht aufweisen
SE9601556D0 (sv) New pharmaceutical formulation of a thrombin inhibitor for parenteral use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1035842

Country of ref document: EP